Cagrilintide (acetate)

Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies[1][2][3].

Product Specifications

UNSPSC

12352209

Target

CGRP Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cagrilintide-acetate.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N)=O)CCC5)=O)[C@@H](C)O)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@@H](C)O)=O)CCC4)=O)CCC3)=O)CC(C)C)=O)[C@H](CC)C)=O)CCC2)=O)=O)CC6=CC=CC=C6)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CO)=O)CC7=CNC=N7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC8=CC=CC=C8)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)[C@@H](C)O)=O)C)=O)NC1=O)=O)CCCCN.O=C(C)O.[x]

Molecular Formula

C194H312N54O59S2.xC2H4O2

Molecular Weight

4409.01 (free base)

References & Citations

[1]Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64 (15) :11183-11194. |[2]Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377 (3) :417-440. |[3]Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30 (4) :320-325.